HK1052655A1 - 用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑 - Google Patents

用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑 Download PDF

Info

Publication number
HK1052655A1
HK1052655A1 HK03105037.1A HK03105037A HK1052655A1 HK 1052655 A1 HK1052655 A1 HK 1052655A1 HK 03105037 A HK03105037 A HK 03105037A HK 1052655 A1 HK1052655 A1 HK 1052655A1
Authority
HK
Hong Kong
Prior art keywords
melatonin
patient
formulation
profile
administration
Prior art date
Application number
HK03105037.1A
Other languages
English (en)
Chinese (zh)
Inventor
纳瓦‧伊莎贝尔
納瓦‧伊莎貝爾
摩西‧劳顿
摩西‧勞頓
Original Assignee
纽里姆药品(1991)有限公司
紐里姆葯品(1991)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 纽里姆药品(1991)有限公司, 紐里姆葯品(1991)有限公司 filed Critical 纽里姆药品(1991)有限公司
Publication of HK1052655A1 publication Critical patent/HK1052655A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Indole Compounds (AREA)
HK03105037.1A 2000-01-05 2000-01-05 用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑 HK1052655A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2000/000009 WO2001049286A1 (en) 2000-01-05 2000-01-05 Method and formulation for treating resistance to antihypertensives and related conditions

Publications (1)

Publication Number Publication Date
HK1052655A1 true HK1052655A1 (zh) 2003-09-26

Family

ID=11042938

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105037.1A HK1052655A1 (zh) 2000-01-05 2000-01-05 用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑

Country Status (31)

Country Link
US (3) US7332177B1 (enExample)
EP (1) EP1272177B1 (enExample)
JP (1) JP4996803B2 (enExample)
CN (1) CN1414851A (enExample)
AT (1) ATE359072T1 (enExample)
AU (1) AU782266B2 (enExample)
BG (1) BG65637B1 (enExample)
BR (1) BR0016918A (enExample)
CA (1) CA2396129C (enExample)
CY (2) CY1108018T1 (enExample)
CZ (1) CZ299931B6 (enExample)
DE (1) DE60034373T2 (enExample)
DK (1) DK1272177T3 (enExample)
EA (1) EA004679B1 (enExample)
EE (1) EE200200379A (enExample)
ES (1) ES2284471T3 (enExample)
HK (1) HK1052655A1 (enExample)
HU (1) HU227002B1 (enExample)
IL (1) IL150190A0 (enExample)
IS (1) IS6439A (enExample)
MX (1) MXPA02005783A (enExample)
NO (1) NO322567B1 (enExample)
NZ (1) NZ520078A (enExample)
PL (1) PL201219B1 (enExample)
PT (1) PT1272177E (enExample)
SI (1) SI1272177T1 (enExample)
SK (1) SK287508B6 (enExample)
TR (1) TR200201724T2 (enExample)
TW (1) TWI260983B (enExample)
UA (1) UA77394C2 (enExample)
WO (1) WO2001049286A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US20050020666A1 (en) * 2003-07-25 2005-01-27 Dabur Research Foundation Cardioprotective agents
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
EP2633376A4 (en) * 2010-10-25 2015-02-18 Uico Inc CONTROL SYSTEM WITH A SOLID-RESISTANT TOUCH SENSOR FOR COMPLEX SURFACE GEOMETRY
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP3500163B1 (en) * 2016-08-18 2025-02-19 Koninklijke Philips N.V. Blood-pressure management
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
HUE070190T2 (hu) 2016-10-31 2025-05-28 Neurim Pharma 1991 Melatonin minitabletták és eljárás azok elõállítására
WO2019038586A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited PHARMACEUTICAL COMPOSITION OF MELATONIN
ES2724933A1 (es) * 2018-03-13 2019-09-17 Ocupharm Diagnostics Sl Terapia combinada con melatonina para la reducción de la presión intraocular
GB2617102A (en) * 2022-03-29 2023-10-04 John Hemming Trading Ltd Sleep therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0518468T3 (da) * 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatoninholdige sammensætninger
WO1993007870A1 (en) * 1991-10-18 1993-04-29 Alza Corporation Device for the transdermal administration of melatonin
US5646049A (en) 1992-03-27 1997-07-08 Abbott Laboratories Scheduling operation of an automated analytical system
SG41955A1 (en) * 1992-04-07 1997-08-15 Neurim Pharma 1991 Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia
EP0664339A4 (en) 1993-07-09 1999-04-28 Wakunaga Seiyaku Kk METHOD FOR DISCRIMINATION OF NUCLEIC ACIDS AND TEST KIT FOR THIS PURPOSE.
NZ298878A (en) 1995-02-01 1999-05-28 Neurim Pharma 1991 Use of melatonin to treat addiction to benzodiazepines
US5648727A (en) 1995-10-24 1997-07-15 Dpc Cirrus Inc. Capacitive level sensing pipette probe
US5700828A (en) 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
AU2583397A (en) * 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии

Also Published As

Publication number Publication date
HU227002B1 (en) 2010-04-28
TWI260983B (en) 2006-09-01
CZ299931B6 (cs) 2008-12-29
US8075914B2 (en) 2011-12-13
DK1272177T3 (da) 2007-08-06
NO20023102L (no) 2002-08-30
ATE359072T1 (de) 2007-05-15
CY2007033I2 (el) 2009-11-04
IL150190A0 (en) 2002-12-01
AU782266B2 (en) 2005-07-14
CA2396129A1 (en) 2001-07-12
WO2001049286A1 (en) 2001-07-12
BR0016918A (pt) 2004-03-23
AU1888200A (en) 2001-07-16
EP1272177B1 (en) 2007-04-11
NO322567B1 (no) 2006-10-30
SI1272177T1 (sl) 2007-10-31
JP4996803B2 (ja) 2012-08-08
MXPA02005783A (es) 2003-10-14
BG65637B1 (bg) 2009-04-30
NO20023102D0 (no) 2002-06-27
ES2284471T3 (es) 2007-11-16
US7332177B1 (en) 2008-02-19
IS6439A (is) 2002-06-24
PT1272177E (pt) 2007-07-11
PL201219B1 (pl) 2009-03-31
CY1108018T1 (el) 2011-04-06
DE60034373T2 (de) 2007-12-20
CZ20022346A3 (cs) 2002-11-13
CY2007033I1 (el) 2009-11-04
CN1414851A (zh) 2003-04-30
US20120070501A1 (en) 2012-03-22
TR200201724T2 (tr) 2003-03-21
CA2396129C (en) 2010-11-30
UA77394C2 (uk) 2006-12-15
BG106978A (en) 2003-03-31
EE200200379A (et) 2003-10-15
PL356325A1 (en) 2004-06-28
DE60034373D1 (de) 2007-05-24
NZ520078A (en) 2004-02-27
SK9732002A3 (en) 2002-11-06
JP2003519181A (ja) 2003-06-17
US8728511B2 (en) 2014-05-20
SK287508B6 (sk) 2010-12-07
EP1272177A1 (en) 2003-01-08
HUP0204089A2 (hu) 2003-04-28
EA200200738A1 (ru) 2002-12-26
US20080085317A1 (en) 2008-04-10
EA004679B1 (ru) 2004-06-24
HUP0204089A3 (en) 2005-12-28
EP1272177A4 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
US8075914B2 (en) Method and formulation for treating resistance to antihypertensives and related conditions
TW389696B (en) Accelerated release composition containing bromocriptine
US6833383B2 (en) Methods for treating patients suffering from drug dependencies which lead to plasma melatonin deficiencies
AU2023202003A1 (en) Melatonin mini-tablets and method of manufacturing the same
JPH10513177A5 (enExample)
CN102274160B (zh) 用于治疗对抗高血压药的抗药性和相关病症的方法和制剂
HK1164136B (en) Method and formulation for treating resistance to antihypertensives and related conditions
IL150190A (en) Use of melatonin in the manufacture of controlled release medicaments for inprovement in mood and daytime vigilance, modifying the 24-hour cortisol profile, protection against carodic ischemia, and prevention or treatment of hypertension in a patient resistant to other antihypertensive drugs
KR20030016215A (ko) 항고혈압제에 대한 내성 및 관련 질환의 치료를 위한 방법및 제형
ZA200206228B (en) Method and formulation for treating resistance to antihypertensives and related conditions.
JP3154750B2 (ja) 外因性カルシウム及びニカルジピンを含む医薬組成物